查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1590911

头颈癌药物市场：按产品、药物类别和最终用户 - 2025-2030 年全球预测

Head & Neck Cancer Drugs Market by Product (Bleomycin, Cetuximab, Docetaxel), Drug Class (Chemotherapy, Immunotherapy, Radiation therapy), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年头颈癌治疗市值为13.5亿美元，预计到2024年将达到15.6亿美元，复合年增长率为15.43%，预计到2030年将达到37亿美元。

头颈癌药物的范围和定义包括为治疗口腔、喉、咽、鼻腔和唾液腺恶性而开发的药物治疗。这些治疗包括化疗、标靶治疗和免疫治疗，旨在抑制癌症生长和扩散。由于吸烟、饮酒和人类乳突病毒（HPV）感染等危险因子导致头颈癌发病率不断上升，这凸显了对这些药物的需求，这需要有效的治疗解决方案。最终用途主要是医院、肿瘤中心和研究机构，应用范围从早期治疗到转移性疾病的管理。市场成长受到人口老化、药物配方进步以及癌症治疗意识增强的显着影响。个人化医疗的引进和生技药品的发展正在创造新的机会，公司正在投资研发以开发副作用较少的标靶治疗。其中包括单株抗体和免疫查核点抑制剂，它们在临床试验中显示出有希望的结果。

主要市场统计
基准年[2023] 13.5亿美元
预测年份 [2024] 15.6亿美元
预测年份 [2030] 37亿美元
复合年增长率（%） 15.43%

然而，市场开拓面临药物开发成本高、法律规范严格、治疗副作用限制患者依从性等挑战。此外，缺乏早期检测技术常常导致诊断较晚，使治疗效果复杂化。需要创新的领域包括加强联合治疗、将人工智慧融入药物发现以及开髮用于早期检测和个人化治疗的新型生物标记。透过专注于这些领域，我们可以透过改善治疗结果和扩大治疗选择来实现业务成长。随着技术的不断进步和治疗通讯协定的不断发展，市场充满活力，需要采取积极主动的方法来应对竞争压力并满足不断变化的患者需求。

市场动态：快速发展的头颈癌药物市场的关键市场洞察

供需的动态交互作用正在改变头颈癌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球头颈癌发生率上升
    • 增加政府和私部门的癌症治疗倡议
    • 头颈癌药物的核准增加
  • 市场限制因素
    • 药品费用高
  • 市场机会
    • 头颈癌药物优惠报销制度
    • 后期管道药物开发的新投资
  • 市场挑战
    • 与药物摄取相关的副作用

波特五力：驾驭头颈癌药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对头颈癌药物市场的影响

外部宏观环境因素在塑造头颈癌治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解头颈癌治疗药物市场的竞争状况

头颈癌治疗药物市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 头颈癌药物市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估头颈癌治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘头颈癌药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，头颈癌药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地头颈癌的发生率正在上升
      • 政府和私部门加强癌症治疗力度
      • 提高头颈癌药物的核准率
    • 抑制因素
      • 药品高成本
    • 机会
      • 头颈癌药物的优惠报销
      • 后期管道药物开发的新投资
    • 任务
      • 与药物摄取相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章头颈癌治疗市场：副产品

  • 博来霉素
  • Cetuximab
  • 多西紫杉醇
  • Erbitux（Cetuximab）
  • Hydrea（羟基尿素）
  • 羟基尿素
  • Keytruda（Pembrolizumab）
  • 胺基甲基叶酸
  • 纳武单抗
  • Opdivo（纳武单抗）
  • Pembrolizumab
  • Taxotere（多西紫杉醇）
  • Trexol（胺基甲基叶酸）

第七章依药物类别分類的头颈癌治疗药物市场

  • 化疗
  • 免疫疗法
  • 放射治疗
  • 外科手术
  • 标靶治疗

第八章头颈癌药物市场：依最终用户分类

  • 癌症研究组织
  • 诊所
  • 医院

第九章北美及南美头颈癌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区头颈癌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲头颈癌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene Ltd.
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Merck & Co., Inc.
  • NEC Corporation
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-43676CF4239E

The Head & Neck Cancer Drugs Market was valued at USD 1.35 billion in 2023, expected to reach USD 1.56 billion in 2024, and is projected to grow at a CAGR of 15.43%, to USD 3.70 billion by 2030.

The scope and definition of head and neck cancer drugs encompass pharmaceutical treatments developed to manage malignancies of the oral cavity, larynx, pharynx, nasal cavity, and salivary glands. These treatments include chemotherapy, targeted therapy, and immunotherapy, designed to inhibit cancer growth and spread. The necessity for these drugs is underscored by the rising incidence of head and neck cancers, driven by risk factors such as tobacco use, alcohol consumption, and human papillomavirus (HPV) infection, which necessitate effective therapeutic solutions. Applications extend from early-stage treatment to metastatic disease management, with end-use primarily in hospitals, oncology centers, and research institutes. Market growth is significantly influenced by the aging population, advancements in drug formulations, and increasing awareness of cancer treatments. The introduction of personalized medicine and development of biologics are creating new opportunities, with companies investing in R&D to develop targeted therapies with fewer side effects. These include monoclonal antibodies and immune checkpoint inhibitors that have shown promising results in clinical trials.

KEY MARKET STATISTICS
Base Year [2023] USD 1.35 billion
Estimated Year [2024] USD 1.56 billion
Forecast Year [2030] USD 3.70 billion
CAGR (%) 15.43%

However, market expansion faces challenges such as high drug development costs, stringent regulatory frameworks, and adverse side effects of treatments that limit patient compliance. Furthermore, the lack of early detection techniques often leads to late-stage diagnoses, complicating treatment efficacy. Areas ripe for innovation include the enhancement of combination therapies, integration of AI in drug discovery, and the development of novel biomarkers for early detection and treatment personalization. Focusing on these areas can drive business growth by improving treatment outcomes and expanding therapeutic options. The market is dynamic, driven by continuous technological advancements and evolving treatment protocols, necessitating a proactive approach to navigate competitive pressures and meet evolving patient demands.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Head & Neck Cancer Drugs Market

The Head & Neck Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of head and neck cancer all across the globe
    • Rise in government and private body initiatives for cancer treatment
    • Increased approval for head & neck cancer drugs
  • Market Restraints
    • High cost of the drugs
  • Market Opportunities
    • Favorable reimbursements for head and neck cancer drugs
    • New investments for developing late-stage pipeline drugs
  • Market Challenges
    • Adverse effect associated with the consumption of the drug

Porter's Five Forces: A Strategic Tool for Navigating the Head & Neck Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Head & Neck Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Head & Neck Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Head & Neck Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Head & Neck Cancer Drugs Market

A detailed market share analysis in the Head & Neck Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Head & Neck Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Head & Neck Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Head & Neck Cancer Drugs Market

A strategic analysis of the Head & Neck Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Head & Neck Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, BeiGene Ltd., Biocon Limited, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corporation, Merck & Co., Inc., NEC Corporation, Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Head & Neck Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Bleomycin, Cetuximab, Docetaxel, Erbitux (Cetuximab), Hydrea (Hydroxyurea), Hydroxyurea, Keytruda (Pembrolizumab), Methotrexate, Nivolumab, Opdivo (Nivolumab), Pembrolizumab, Taxotere (Docetaxel), and Trexall (Methotrexate).
  • Based on Drug Class, market is studied across Chemotherapy, Immunotherapy, Radiation therapy, Surgery, and Targeted Therapy.
  • Based on End User, market is studied across Cancer Research Institutes, Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of head and neck cancer all across the globe
      • 5.1.1.2. Rise in government and private body initiatives for cancer treatment
      • 5.1.1.3. Increased approval for head & neck cancer drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable reimbursements for head and neck cancer drugs
      • 5.1.3.2. New investments for developing late-stage pipeline drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effect associated with the consumption of the drug
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Head & Neck Cancer Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Bleomycin
  • 6.3. Cetuximab
  • 6.4. Docetaxel
  • 6.5. Erbitux (Cetuximab)
  • 6.6. Hydrea (Hydroxyurea)
  • 6.7. Hydroxyurea
  • 6.8. Keytruda (Pembrolizumab)
  • 6.9. Methotrexate
  • 6.10. Nivolumab
  • 6.11. Opdivo (Nivolumab)
  • 6.12. Pembrolizumab
  • 6.13. Taxotere (Docetaxel)
  • 6.14. Trexall (Methotrexate)

7. Head & Neck Cancer Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Immunotherapy
  • 7.4. Radiation therapy
  • 7.5. Surgery
  • 7.6. Targeted Therapy

8. Head & Neck Cancer Drugs Market, by End User

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Head & Neck Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Head & Neck Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Head & Neck Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. BeiGene Ltd.
  • 5. Biocon Limited
  • 6. Bristol-Myers Squibb Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Gilead Sciences, Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Incyte Corporation
  • 11. Merck & Co., Inc.
  • 12. NEC Corporation
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. HEAD & NECK CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. HEAD & NECK CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEAD & NECK CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEAD & NECK CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEAD & NECK CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY BLEOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CETUXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ERBITUX (CETUXIMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDREA (HYDROXYUREA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY KEYTRUDA (PEMBROLIZUMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY OPDIVO (NIVOLUMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXOTERE (DOCETAXEL), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TREXALL (METHOTREXATE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 95. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 159. HEAD & NECK CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023